Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CASR | P41180 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clobenzorex SCHEMBL26720 | 0.85 | LMNA (1.00) | LMNASIGMAR1L3MBTL1POLBMAPK1 | |
| Clobenzorex SCHEMBL31080692 | 0.85 | LMNA (1.00) | LMNASIGMAR1L3MBTL1POLBMAPK1 | |
| SCHEMBL7049977 | 0.83 | SIGMAR1 (0.54) | LMNAMEN1KMT2ASIGMAR1L3MBTL1 | |
| SCHEMBL30207393 | 0.83 | SIGMAR1 (0.54) | LMNAMEN1KMT2ASIGMAR1L3MBTL1 | |
| Clobenzorex SCHEMBL1649957 | 0.82 | LMNA (0.94) | LMNASIGMAR1L3MBTL1POLBMAPK1 | |
| SCHEMBL8587899 | 0.82 | LMNA (0.71) | LMNACASRSIGMAR1L3MBTL1POLB | |
| SCHEMBL593666 | 0.81 | SIGMAR1 (0.74) | MEN1KMT2ASIGMAR1L3MBTL1 | |
| SCHEMBL719011 | 0.81 | SIGMAR1 (0.74) | MEN1KMT2ASIGMAR1L3MBTL1 | |
| SCHEMBL2795948 | 0.81 | SIGMAR1 (0.74) | MEN1KMT2ASIGMAR1L3MBTL1 | |
| SCHEMBL8092326 | 0.81 | SIGMAR1 (0.74) | MEN1KMT2ASIGMAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659277-B2 | Ubiquitin ligase inhibitors and methods related thereto | Proteologies, Ltd. (IL) | 2010-02-09 | — | — | US | disclosed |
| US-7659277-B2 | Ubiquitin ligase inhibitors and methods related thereto | Proteologies, Ltd. (IL) | 2010-02-09 | — | — | US | disclosed |
| US-20070015768-A1 | Ubiquitin ligase inhibitors and methods related thereto | PROTEOLOGICS, LTD. (IL) | 2007-01-18 | — | — | US | disclosed |
| US-20070015768-A1 | Ubiquitin ligase inhibitors and methods related thereto | PROTEOLOGICS, LTD. (IL) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015768-A1 | Ubiquitin ligase inhibitors and methods related thereto | XIAP, NEDD4, MDM2 | LMNA 3288/4885CASR 4812/4885MEN1 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.